Recurrent disease after treatment for cervical pre-cancer: determining whether prophylactic HPV vaccination could play a role in prevention of secondary lesions

References

• Schiffman MH, Bauer HM, Hoover RN, et al. Epidemiologic evidence showing that human papillomavirus infection causes most cervical intraepithelial neoplasia. J Natl Cancer Inst 1993;85:958–64
   PubMed Web of Science ®Google Scholar
• Globocan Cancer Fact Sheets. Cervical cancer, estimated incidence, mortality and prevalence worldwide in 2018. http://gco.iarc.fr/today/data/factsheets/cancers/23-Cervix-uteri-fact-sheet.pdf [last accessed 7 Feb 2019]
   Google Scholar
• World Health Organization. Reproductive health. WHO leads the way towards the elimination of cervical cancer as a public health concern. https://www.who.int/reproductivehealth/cervical-cancer-public-health-concern/en/ [last accessed 7 Feb 2019].
   Google Scholar
• World Health Organization. Cervical cancer: An NCD we can overcome. May 2019 https://www.who.int/reproductivehealth/DG_Call-to-Action.pdf [last accessed 1 Feb 2019].
   Google Scholar
• National HPV Vaccination Program Register. Coverage data. http://www.hpvregister.org.au/research/coverage-data [last accessed 13 Feb 2019].
   Google Scholar
• Hall MT, Simms KT, Lew JB, et al. The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health 2019;4:e19–27
   PubMed Web of Science ®Google Scholar
• van Doorn LJ, Molijn A, Kleter B, et al. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006;44:3292–8
   PubMed Web of Science ®Google Scholar
• Dochez C, Bogers JJ, Verhelst R, Rees H. HPV vaccines to prevent cervical cancer and genital warts: an update. Vaccine 2014;32:1595–601
   PubMed Web of Science ®Google Scholar
• Cervarix® product information. https://www.gsk.com.au/resources.ashx/vaccineproductschilddataproinfo/496/FileName/3E81056AE2FE8CAE629CF2AEB25C5463/Cervarix_PI_010_Approved.pdf [last accessed 7 Feb 2019]
   Google Scholar
• Gardasil® product information. https://www.seqirus.com.au/docs/392/563/Gardasil%20PI%20A160204,0.pdf [last accessed 7 Feb 2019]
   Google Scholar
• Gardasil 9® product information. https://www.seqirus.com.au/docs/261/575/Gardasil%209%20PI%20.pdf [last accessed 7 Feb 2019].
   Google Scholar
• Block SL, Nolan T, Sattler C, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalenthuman papillomavirus (types 6: 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006;118:2135–45
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsagué X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30S:F123–38
   Google Scholar
• Thamsborg LH, Napolitano G, Larsen LG, Lynge E. Impact of HPV-vaccination on outcome of cervical cytology screening in Denmark – a register based cohort study. Int J Cancer 2018;143:1662–70
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. Cervical screening in Australia 2014–2015. Cancer series no. 105. Cat. no. CAN 104. Canberra: AIHW; 2017
   Google Scholar
• Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L. Quadrivalent HPV vaccine effectiveness against high-grade cervical lesions by age at vaccination: A population-based study. Int J Cancer 2016;138:2867–74
   PubMed Web of Science ®Google Scholar
• Arbyn M, Xu L, Simoens C, Martin‐Hirsch PPL. Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors. Cochrane Database Syst Rev 2018;CD009069
   PubMed Web of Science ®Google Scholar
• Hall MT, Simms KT, Lew JB, et al. Projected future impact of HPV vaccination and primary HPV screening on cervical cancer rates from 2017-2035: example from Australia. PLoS One 2018;13:e0185332
   PubMed Web of Science ®Google Scholar
• Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. Lancet 2014;384:2213–27
   PubMed Web of Science ®Google Scholar
• Muñoz N, Manalastas R, Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373:1949–57
   PubMed Web of Science ®Google Scholar
• Gravitt PE, Winer RL. Natural history of HPV infection across the lifespan: role of viral latency. Viruses 2017;9:267
   Web of Science ®Google Scholar
• Rositch AF, Soeters HM, Offutt-Powell TN, et al. The incidence of human papillomavirus infection following treatment for cervical neoplasia: a systematic review. Gynecol Oncol 2014;132:767–79
   PubMed Web of Science ®Google Scholar
• Kyrgiou M, Athanasiou A, Paraskevaidi M, et al. Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis. BMJ 2016;354:i3633
   PubMed Web of Science ®Google Scholar
• Martin-Hirsch PP, Paraskevaidis E, Bryant A, Dickinson HO. Surgery for cervical intraepithelial neoplasia. Cochrane Database Syst Rev 2013;CD001318
   PubMed Web of Science ®Google Scholar
• Cancer Council Australia Cervical Cancer Screening Guidelines Working Party. National Cervical Screening Program: Guidelines for the management of screen-detected abnormalities, screening in specific populations and investigation of abnormal vaginal bleeding. Sydney, Australia: Cancer Council Australia. https://wiki.cancer.org.au/australia/Guidelines:Cervical_cancer/Screening [last accessed 8 February 2019]
   Google Scholar
• Hoffman SR, Le T, Lockhart A, et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN): a systematic review. Int J Cancer 2017;141:8–23
   PubMed Web of Science ®Google Scholar
• Arbyn M, Redman CWE, Verdoodt F, et al. Incomplete excision of cervical precancer as a predictor of treatment failure: a systematic review and meta-analysis. Lancet Oncol 2017;18:1665–79
   PubMed Web of Science ®Google Scholar
• Tan JH, Garland SM, Tabrizi SN, Moore EE, Danielewski JA, Quinn MA. Hybrid Capture II testing for high-risk human papillomavirus DNA in the follow-up of women treated for high-grade cervical intraepithelial neoplasia. J Low Genit Tract Dis 2013;17:308–14
   PubMed Web of Science ®Google Scholar
• Arbyn M, Ronco G, Anttila A, et al. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. Vaccine 2012;30: Suppl F88–99
   PubMedGoogle Scholar
• Garland SM, Paavonen J, Jaisamrarn U, et al. Prior human papillomavirus-16/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial. Int J Cancer 2016;139:2812–26
   PubMed Web of Science ®Google Scholar
• Gosvig CF, Huusom LD, Andersen KK, et al. Long-term follow-up of the risk for cervical intraepithelial neoplasia grade 2 or worse in HPV-negative women after conization. Int J Cancer 2015;137:2927–33
   PubMed Web of Science ®Google Scholar
• Del Mistro A, Matteucci M, Insacco EA, et al. Long-term clinical outcome after treatment for high-grade cervical lesions: a retrospective monoinstitutional cohort study. Biomed Res Int 2015;2015:1
   Google Scholar
• Serati M, Siesto G, Carollo S, et al. Risk factors for cervical intraepithelial neoplasia recurrence after conization: a 10-year study. Eur J Obstet Gynecol Reprod Biol 2012;165:86–90
   PubMed Web of Science ®Google Scholar
• Ghaem-Maghami S, De-Silva D, Tipples M, et al. Determinants of success in treating cervical intraepithelial neoplasia. BJOG 2011; 118:679–84
   PubMed Web of Science ®Google Scholar
• Strander B, Hällgren J, Sparén P. Effect of ageing on cervical or vaginal cancer in Swedish women previously treated for cervical intraepithelial neoplasia grade 3: population based cohort study of long term incidence and mortality. BMJ 2014;348:f7361
   PubMedGoogle Scholar
• Rebolj M, Helmerhorst T, Habbema D, et al. Risk of cervical cancer after completed post-treatment follow-up of cervical intraepithelial neoplasia: population based cohort study. BMJ 2012;345:e6855
   PubMed Web of Science ®Google Scholar
• Kocken M, Helmerhorst TJ, Berkhof J, et al. Risk of recurrent high-grade cervical intraepithelial neoplasia after successful treatment: a long-term multi-cohort study. Lancet Oncol 2011;12:441–50
   PubMed Web of Science ®Google Scholar
• Melnikow J, McGahan C, Sawaya GF, Ehlen T, Coldman A. Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia Cohort Study. J Natl Cancer Inst 2009;101:721–8
   PubMedGoogle Scholar
• Soutter WP, Sasieni P, Panoskaltsis T. Long-term risk of invasive cervical cancer after treatment of squamous cervical intraepithelial neoplasia. Int J Cancer 2006;118:2048–55
   PubMed Web of Science ®Google Scholar
• Kalliala I, Anttila A, Pukkala E, Nieminen P. Risk of cervical and other cancers after treatment of cervical intraepithelial neoplasia: retrospective cohort study. BMJ 2005;331:1183–5
   PubMed Web of Science ®Google Scholar
• Ebisch RMF, Rutten DWE, IntHout J, et al. Long-lasting increased risk of human papillomavirus-related carcinomas and premalignancies after cervical intraepithelial neoplasia grade 3: a population-based cohort study. JCO 2017;35:2542–50
   PubMed Web of Science ®Google Scholar
• van der Heijden E, Lopes AD, Bryant A, et al. Follow-up strategies after treatment (large loop excision of the transformation zone (LLETZ)) for cervical intraepithelial neoplasia (CIN): impact of human papillomavirus (HPV) test. Cochrane Database Syst Rev 2015;1:CD010757
   PubMedGoogle Scholar
• Katki HA, Schiffman M, Castle PE, et al. Five-year risk of recurrence after treatment of CIN 2, CIN 3, or AIS: performance of HPV and Pap cotesting in posttreatment management. J Low Genit Tract Dis 2013;17:S78–S84
   PubMed Web of Science ®Google Scholar
• Uijterwaal MH, Kocken M, Berkhof J, et al. Posttreatment assessment of women at risk of developing high-grade cervical disease: proposal for new guidelines based on data from the Netherlands. J Low Genit Tract Dis 2014;18:338–43
   PubMed Web of Science ®Google Scholar
• Cuschieri K, Bhatia R, Cruickshank M, Hillemanns P, Arbyn M. HPV testing in the context of post-treatment follow up (test of cure). J Clin Virol 2016;76: Suppl S56–S61
   PubMedGoogle Scholar
• National Health and Medical Research Council. Screening to prevent cervical cancer: guidelines for the management of asymptomatic women with screen detected abnormalities. Canberra: NHMRC; 2005.
   Google Scholar
• Morrell S, Qian L. A whole-population profile of HPV testing as a test of cure for high-grade cervical dysplasia in NSW, Australia. J Med Screen 2014;21:151–62
   PubMed Web of Science ®Google Scholar
• Legood R, Smith M, Lew JB, et al. Cost effectiveness of human papillomavirus test of cure after treatment for cervical intraepithelial neoplasia in England: economic analysis from NHS sentinel sites study. BMJ 2012;345:e7086
   PubMed Web of Science ®Google Scholar
• Hildesheim A, Herrero R, Wacholder S, et al. Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. JAMA 2007;298:743–53
   PubMed Web of Science ®Google Scholar
• Haupt RM, Wheeler CM, Brown DR, et al. Impact of an HPV6/11/16/18 L1 virus-like particle vaccine on progression to cervical intraepithelial neoplasia in seropositive women with HPV16/18 infection. Int J Cancer 2011;129:2632–42
   PubMed Web of Science ®Google Scholar
• Szarewski A, Poppe WAJ, Skinner SR, et al. Efficacy of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure to HPV-16/18. Int J Cancer 2012;131:106–16
   PubMed Web of Science ®Google Scholar
• Joura EA, Garland SM, Paavonen J, et al. Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data. BMJ 2012;344:e1401
   PubMedGoogle Scholar
• Hildesheim A, Gonzalez P, Kreimer AR, et al. Impact of human papillomavirus (HPV) 16 and 18 vaccination on prevalent infections and rates of cervical lesions after excisional treatment. Am J Obstet Gynecol 2016;215:212.e1–.e15
   PubMed Web of Science ®Google Scholar
• Kang WD, Choi HS, Kim SM. Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2-3)? Gynecol Oncol 2013;130:264–8
   PubMed Web of Science ®Google Scholar
• Ghelardi A, Parazzini F, Martella F, et al. SPERANZA project: HPV vaccination after treatment for CIN2. Gynecol Oncol 2018;151:229–34
   PubMed Web of Science ®Google Scholar
• Velentzis LS, Smith MA, Simms KT, et al. Pathways to a cancer-free future: a protocol for modelled evaluations to maximize the future impact of interventions on cervical cancer in Australia. Gynecol Oncol 2019;152:465–71
   PubMed Web of Science ®Google Scholar
• Bosch FX, Robles C, Díaz M, et al. HPV-FASTER: broadening the scope for prevention of HPV-related cancer. Nat Rev Clin Oncol 2016;13:119–32
   PubMed Web of Science ®Google Scholar
• Simms KT, Steinberg J, Caruana M, et al. Impact of scaled up human papillomavirus vaccination and cervical screening and the potential for global elimination of cervical cancer in 181 countries, 2020–99: a modelling study. Lancet Oncol 2019;20:S1470–S2045
   PubMed Web of Science ®Google Scholar
• Simms K, Smith MA, Brotherton JML, et al. Population-level effectiveness and cost-effectiveness of HPV-FASTER in low-resource settings and high-resource settings. Oral presentation. 32nd International Papillomavirus Conference; 2018 Oct 2–6; Sydney, Australia
   Google Scholar